查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球临床诊断市场 2023-2030
市场调查报告书
商品编码
1350991

全球临床诊断市场 2023-2030

Global Clinical Diagnostics Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 133 Pages | 商品交期: 2-3个工作天内

价格

在预测期内（2023-2030年），全球临床诊断市场预计将以 6.3% 的复合年增长率成长。市场扩张归因于创新诊断测试的持续现代化。新一代定序 (NGS)、分子诊断和新成像技术等技术进步大大提高了诊断测试的精确度和功效。引入一种创新的生物标记测试，能够准确识别前列腺癌并估计其进展的严重程度，可能对患者管理产生重大影响。这项创新有可能改善风险分层、个人化治疗方法并减少不必要的医疗干预。

随着医疗保健部门继续优先考虑精准医疗和以患者为中心的治疗，增强型生物标记测试的发展与这些目标是一致的。因此，主要市场参与者正在积极推出新颖产品，以满足对先进生物标记测试不断增长的需求。例如，2023 年 7 月，Quest Diagnostics 与 Envision Sciences 的亚专业病理学子公司 AmeriPath 合作推出了一项创新的前列腺癌生物标记测试。 Envision Sciences Pty Ltd. 是一家澳洲临床诊断企业，致力于开发一系列基于血液和组织的癌症诊断和预后测试，充分利用生物标记的潜力。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Bio-Rad Laboratories, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Danaher Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Sysmex Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按测试分類的全球临床诊断市场
    • 脂质面板
    • 肝臟面板
    • 肾臟检查
    • 全血球计数
    • 电解质测试
    • 传染病检测
    • 其他（基因检测、心电图、心臟压力测试）
  • 按产品分類的全球临床诊断市场
    • 仪器
    • 试剂
    • 其他（检测和试剂盒）
  • 全球临床诊断市场（按最终用户）
    • 医院实验室
    • 诊断实验室
    • 即时检测

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Abbott
  • Cepheid
  • Charles River Laboratories International, Inc.
  • Exact Sciences Corp.
  • Flagship Biosciences, Inc.
  • FUJIFILM Holdings Corp.
  • LGC Clinical Diagnostics
  • Merck Group
  • NeoGenomics Laboratories, Inc.
  • Ortho Clinical Diagnostics
  • SCIEX
  • Sonic Healthcare Ltd.
  • Thermo Fisher Scientific
Product Code: OMR2027585

Title: Global Clinical Diagnostics Market Size, Share & Trends Analysis Report by Test (Lipid Panel, Liver Panel, Renal Panel, Complete Blood Count, Electrolyte Testing, Infectious Disease Testing, and Others), by Product (Instruments, Reagents, and Others), and by End-User (Hospital Laboratory, Diagnostic Laboratory, and Point-of-Care Testing),Forecast Period (2023-2030).

The global clinical diagnostics market is anticipated to grow at a CAGR of 6.3% during the forecast period (2023-2030). The market expansion is attributed to the ongoing modernization of innovative diagnostic tests. Technological advancements, such as next-generation sequencing (NGS), molecular diagnostics, and new imaging techniques, have substantially enhanced the precision and efficacy of diagnostic tests. Introducing an innovative biomarker test capable of accurately recognizing prostate cancer and estimating the severity of its progression could have significant implications for patient management. This innovation has the potential to lead to improved risk stratification, personalized treatment approaches, and a reduction in unnecessary medical interventions.

The development of enhanced biomarker testing is consistent with these objectives as the healthcare sector continues to prioritize precision medicine and patient-centered treatment. Consequently, key market players are actively introducing novel products to meet the rising demand for advanced biomarker tests. For instance, in July 2023, Quest Diagnostics launched an innovative prostate cancer biomarker test in collaboration with Envision Sciences' sub-specialty pathology subsidiary AmeriPath. Envision Sciences Pty Ltd., an Australian clinical diagnostics enterprise, is engaged in developing a portfolio of blood and tissue-based tests for cancer diagnosis and prognosis, leveraging the potential of biomarkers.

This concentrated focus on innovation highlights the industry's dedication to enhance diagnostic capabilities and emphasizes its commitment to advancing patient care through state-of-the-art technologies and methodologies.

Segmental Outlook

The global clinical diagnostics market is segmented by test, product, and end-user. Based on the test, the market is sub-segmented into lipid panels, liver panels, renal panels, complete blood counts, electrolyte testing, infectious disease testing, and others. Based on the product, the market is sub-segmented into instruments, reagents, and others. Further, on the basis of end-user, the market is sub-segmented into hospital laboratories, diagnostic laboratories, point-of-care testing, and others. Among the end-users, the point-of-care testing sub-segment is anticipated to hold a considerable share of the market owing to the healthcare industry's significant shift towards decentralization along with the rapidly increasing utilization of point-of-care diagnostic products.

The Lipid Panel Sub-Segment is Anticipated to Hold a Considerable Share of the Global Clinical Diagnostics Market

Among the tests, the lipid panel sub-segment is expected to hold a considerable share of the global clinical diagnostics market. The segmental growth is attributed to the growing health awareness. More individuals are opting for lipid panel tests and engaging in discussions with healthcare professionals about their cardiovascular well-being owing to increased understanding of the importance of maintaining optimal/ good cholesterol levels. For instance, in June 2023, the British Heart Foundation reported that heart and circulatory diseases encompass a variety of conditions related to the heart and blood vessels. These conditions include inherited diseases, coronary heart disease, atrial fibrillation, heart failure, stroke, and vascular dementia. The global count of individuals affected by heart or circulatory diseases is approximately 620 million, and this number continuous to increase due to changing lifestyles, an aging population, and improved survival rates following heart attacks and strokes. Approximately 1 in 13 people globally are estimated to live with these conditions. In 2019, there were 290 million women and 260 million men living with heart or circulatory diseases. Since 1997, this count has more than doubled, escalating from 285 million to 620 million. The most common conditions are coronary heart disease, peripheral vascular disease, stroke, and atrial fibrillation. Every year, an estimated 60 million individuals globally develop heart or circulatory diseases.

In 2019, the incidence rate for coronary heart disease was 8.7 million, for peripheral vascular disease was 4.5 million, for stroke was 8.4 million, and for atrial fibrillation was 1.3 million. This growing awareness of heart and circulatory diseases and their impact on health has led to an increased demand for diagnostic tests and medical guidance, subsequently driving the growth of specific market segments.

Regional Outlook

The global clinical diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe. This growth is contributed owing to the higher patient understanding the importance of laboratory tests, and a rise in the number of individuals with infectious and long-term illnesses. For instance, around 1.9 million new cancer cases were diagnosed in the US, according to the American Cancer Society report published in 2022.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Clinical Diagnostics Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing demand for early detection of diseases. Diagnostic tests that can identify diseases in their initial stages are considered beneficial, as they may improve the chances of successful treatment and potentially reduce associated healthcare costs. Further expansion of diagnostic centers across the region is creating favorable conditions for the growth of the market. For instance, in February 2023, The Centre for Cellular and Molecular Platforms (C-CAMP) launched the National Diagnostics Catapult (C-CAMP InDx 2.0) in New Delhi. The Catapult, C-CAMP InDx 2.0, is intended to strengthen India's readiness for existing and potential pandemics and expand the diagnostic area for contagious diseases, such as COVID-19. Furthermore, the Catapult is designed to create a global model for capacity building in the diagnostics field in lower- and middle-income countries (LMICs) to accomplish the two objectives of affordability and accessibility in the global vision for Universal Health Coverage.

Market Players Outlook

The major companies serving the clinical diagnostics market include: Abbott, Cepheid, Charles River Laboratories International, Inc., Exact Sciences Corp., Flagship Biosciences, Inc., and others. The market players are considerably contributing to market growth through the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2022, Qiagen Inc. launched the NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) with approval from the European Commission.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global clinical diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bio-Rad Laboratories, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Danaher Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Sysmex Corp.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Clinical Diagnostics Market by Test
    • 4.1.1. Lipid Panel
    • 4.1.2. Liver Panel
    • 4.1.3. Renal Panel
    • 4.1.4. Complete Blood Count
    • 4.1.5. Electrolyte Testing
    • 4.1.6. Infectious Disease Testing
    • 4.1.7. Others (Genetic Testing, Electrocardiography, and Cardiac Stress Test)
  • 4.2. Global Clinical Diagnostics Market by Product
    • 4.2.1. Instruments
    • 4.2.2. Reagents
    • 4.2.3. Others (Assays, and Kits)
  • 4.3. Global Clinical Diagnostics Market by End-User
    • 4.3.1. Hospital Laboratory
    • 4.3.2. Diagnostic Laboratory
    • 4.3.3. Point-of-Care Testing

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott
  • 6.2. Cepheid
  • 6.3. Charles River Laboratories International, Inc.
  • 6.4. Exact Sciences Corp.
  • 6.5. Flagship Biosciences, Inc.
  • 6.6. FUJIFILM Holdings Corp.
  • 6.7. LGC Clinical Diagnostics
  • 6.8. Merck Group
  • 6.9. NeoGenomics Laboratories, Inc.
  • 6.10. Ortho Clinical Diagnostics
  • 6.11. SCIEX
  • 6.12. Sonic Healthcare Ltd.
  • 6.13. Thermo Fisher Scientific

LIST OF TABLES

  • 1. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 2. GLOBAL LIPID CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL LIVER CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RENAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL COMPLETE BLOOD COUNT CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ELECTROLYTE TESTING CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL INFECTIOUS DISEASE TESTING CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHERS CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 10. GLOBAL INSTRUMENTS BASED CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL REAGENTS BASED CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 12. GLOBAL OTHER PRODUCTS BASED CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. GLOBAL CLINICAL DIAGNOSTICS IN HOSPITAL LABORATORY MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL CLINICAL DIAGNOSTICS IN DIAGNOSTIC LABORATORY MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 16. GLOBAL CLINICAL DIAGNOSTICS IN POINT-OF-CARE TESTING MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 17. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 24. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE BY TEST, 2022 VS 2030 (%)
  • 2. GLOBAL LIPID CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL LIVER CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RENAL CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL COMPLETE BLOOD COUNT CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ELECTROLYTE TESTING CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL INFECTIOUS DISEASE TESTING CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OTHERS CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 10. GLOBAL INSTRUMENTS BASED CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL REAGENTS BASED CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OTHER PRODUCTS BASED CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. GLOBAL CLINICAL DIAGNOSTICS IN HOSPITAL LABORATORY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CLINICAL DIAGNOSTICS IN DIAGNOSTIC LABORATORY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL CLINICAL DIAGNOSTICS IN POINT-OF-CARE TESTING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)